Prothena to Highlight Next Generation Treatments for Alzheimer's and Parkinson's Disease at AD/PD 2023 Meeting

Prothena to Spotlight Subsequent Technology Therapies for Alzheimer’s and Parkinson’s Illness at AD/PD 2023 Assembly

  • Broad Attendance at This Yr’s Congress Highlights Prothena’s Management in Advancing Subsequent Technology Therapies for Alzheimer’s and Parkinson’s Illness

  • Oral presentation of PRX012, Prothenas next-generation amyloid-beta antibody for Alzheimer’s illness, demonstrates larger affinity binding to amyloid-beta protofibrils and better clearance of amyloid-beta-pyroglutamate plaques in comparison with different accredited and experimental molecules

  • Prothena Participates in Alzheimer’s AD/PD Discussion board Discussions and Hosts an Business-Sponsored Symposium

  • Roche Accomplice Symposium Posters and Shows on the Section 2 PASADENA Examine of Prasinezumab for Parkinson’s Illness

DUBLIN, March 14, 2023–(BUSINESS WIRE)–Prothena Company plc (NASDAQ:PRTA), an late-stage medical biotechnology firm with a strong pipeline of investigational therapeutics based mostly on experience in protein dysregulation, at the moment introduced broad participation within the 2023 Worldwide Convention on Alzheimer’s and Parkinson’s Ailments and Associated Neurological Issues (AD/PD) to be held March 28-April 1, 2023 in Gothenburg, Sweden, highlighting Prothena’s management in advancing next-generation therapies for the Alzheimer’s illness and Parkinson’s illness.

PRX012 for the remedy of Alzheimer’s illness

In an oral presentation, Prothena will focus on new preclinical information from its PRX012 program, a possible best-in-class anti-amyloid-beta (A) product candidate underneath improvement for the remedy of Alzheimer’s illness. To realize a deeper understanding of the binding profile of PRX012 to protofibrils A and its capability to clear pyroglutamate-A from Alzheimer’s illness mind tissue, nonclinical research in contrast a PRX012 surrogate* (PRX012s) to accredited and experimental molecules. Outcomes demonstrated that PRX012 had superior binding with 20-fold affinity to protofibrils A in comparison with lecanemab+ and extra strong phagocytic-mediated clearance of pyroglutamate-modified A than donanemab+.

These outcomes additional help the continuing medical improvement of PRX012 as a possible best-in-class remedy for Alzheimer’s illness that would permit for better accessibility and extra handy administration for sufferers and healthcare suppliers.

Beneath are the main points of the oral presentation PRX012 AD/PD 2023:

  • Session kind: Symposium

  • Title: Abeta focusing on therapies in AD 02

  • Oral presentation: Binding traits of PRX012 surrogate reveal potent involvement of poisonous Abeta protofibrils and strong clearance of pyroglutamate-modified Abeta

  • Presenting writer: Brian Campbell

  • Summary quantity: 2480

  • Date: Friday, March 31, 2023

  • Hours: 2:20 PM CET (9:20 AM EDT)

  • Location: Pavilion C of the Swedish Exhibition Heart Gothenburg

  • Summary:

Extra Prothena sponsored actions at AD/PD 2023

Prothena to host leaders in Alzheimer’s illness analysis to outline the following technology of affected person care at a company-sponsored symposium:

  • Title: Getting into the Period of Illness-Modifying Therapies for AD: Taking inventory of at the moment and trying to tomorrow

  • Symposium Chair: Dr. Dennis Selkoe, Co-Director, Ann Romney Heart for Neurologic Ailments, Division of Neurology, Brigham and Girls’s Hospital, Harvard Medical College

  • Audio system: Dr. Jeffrey Cummings, Pleasure Chambers-Grundy Professor of Mind Science and Director, Chambers-Grundy Heart for Transformative Neuroscience, College of Nevada Las Vegas (UNLV); and Dr. Alireza Atri, Director, Banner Solar Well being Analysis Institute, Banner Well being, Solar Metropolis, Arizona

  • Date: Thursday, March 30, 2023

  • Hours: 08:40-10:40 CET (3:40-5:40 AM EDT)

  • Location: Pavilion C of the Swedish Exhibition Heart Gothenburg

Prothena may even take part in two AD/PD 2023 discussion board discussions:

  • Title: Immunotherapies in AD: from fundamentals to approval

  • Speaker: Wagner Zago, scientific director, Prothena

  • Date: Wednesday, March 29, 2023

  • Hours: 3:55pm-4:55pm CET (11:55am-12:55pm EDT)

  • Location: Pavilion C of the Swedish Exhibition Heart Gothenburg

  • Title: Anti-tau therapies in medical trials

  • Speaker: Phillip Dolan, Sr. Director, Head of Exploratory Analysis, Prothena

  • Date: Friday, March 31, 2023

  • Hours: 5:20-6:20 PM CET (12:20-1:20 PM EDT)

  • Location: Pavilion C of the Swedish Exhibition Heart Gothenburg

Roche (companion) Shows on Prasinezumab for the remedy of Parkinson’s illness

  • On-Demand Symposium: Digital Well being Applied sciences Can Scale back Pattern Sizes and Allow Shorter Proof-of-Idea Scientific Trial in Parkinson’s Illness (OD059 / #1444)

  • Date: Wednesday, March 29, 2023

  • Hours: 07:00-08:30 CET (2:00-3:30 AM EDT)

  • On-Demand Symposium: Reliability and Validity of Digital Speech Options as Biomarkers of Dysarthria Severity and Development in People with Early-Stage Parkinson’s Illness (OD058 / #1082)

  • Date: Wednesday, March 29, 2023

  • Hours: 07:00-08:30 CET (2:00-3:30 AM EDT)

About PRX012
PRX012, an investigational next-generation anti-A antibody, was designed as a subcutaneous IgG1 mAb to focus on aggregated types of A, together with protofibrils and plaques, with excessive binding affinity. PRX012 is at the moment being investigated in a Section 1 medical trial for the remedy of Alzheimer’s illness. Preclinical information demonstrated the binding of PRX012 to amyloid-beta plaques and oligomers with excessive affinity, permitting for efficient occupation and removing of plaque A at comparatively decrease dose ranges, optimum for subcutaneous administration. Preclinical information additionally demonstrated the clearance of modified and unchanged plaque A of pyroglutamate in mind tissue at PRX012 concentrations estimated to be clinically achievable within the central nervous system with subcutaneous administration.

About Alzheimer’s illness
Alzheimer’s illness is a life-threatening illness and the most typical type of dementia that causes more and more extreme signs, together with confusion, disorientation, modifications in temper and conduct, and issue talking, swallowing, and strolling. An estimated 55 million individuals worldwide reside with Alzheimer’s illness or different types of dementia. Alzheimer’s illness is the most typical neurodegenerative illness. There may be an pressing want for therapies that sluggish the development and finally forestall Alzheimer’s illness to deal with this world well being disaster. Prothenas’ Alzheimer’s illness portfolio contains next-generation antibody, small molecule and vaccine immunotherapy approaches, geared in direction of constructing first-generation therapies to advance the therapeutic paradigm.

About Prasinezumab
Prasinezumab is a humanized monoclonal antibody that targets a carboxyl terminal epitope of alpha-synuclein, a protein present in neurons that may mixture and unfold from cell to cell, ensuing within the neuronal dysfunction and loss that trigger Parkinson’s illness. Prasinezumab is designed to dam cell-to-cell transmission of the aggregated pathogenic types of alpha-synuclein in Parkinson’s illness, thereby slowing medical decline. In December 2013, Prothena and Roche entered right into a worldwide collaboration to develop and commercialize antibodies focusing on alpha-synuclein, together with prasinezumab. For extra info on the Section 2b PADOVA medical trial of prasinezumab in sufferers with early stage Parkinson’s illness, please go to (NCT#04777331).

On Parkinson’s illness
Parkinson’s illness is a progressive degenerative illness of your complete nervous system that impacts one in 100 individuals over the age of 60. An estimated seven to 10 million individuals reside with Parkinson’s illness worldwide. It’s the second commonest neurodegenerative illness after Alzheimer’s illness. The illness is characterised by neuronal accumulation of aggregated alpha-synuclein within the central nervous system and peripheral nervous system leading to a broad spectrum of progressive worsening of motor and nonmotor signs. Whereas the analysis relies on the motor signs classically related to Parkinson’s illness, non-motor signs can current a few years earlier. Present therapies for Parkinson’s illness are symptomatic and handle solely a subset of signs akin to motor impairment, dementia or psychosis. There are at the moment no therapies out there that focus on the underlying reason behind the illness and may sluggish its development.

About Prothena
Prothena Company plc is an advanced-stage medical biotechnology firm with experience in protein dysregulation and a pipeline of investigational therapeutics with the potential to vary the course of the devastating neurodegenerative and uncommon peripheral amyloid ailments. Fueled by its deep scientific experience constructed over many years of analysis, Prothena is advancing a pipeline of therapeutic candidates for quite a lot of indications and new targets for which its capability to combine scientific insights into neurological dysfunction and protein biology are folded may be exploited. The Prothenas pipeline contains each wholly owned and collaborative packages in improvement for the potential remedy of ailments together with AL amyloidosis, ATTR amyloidosis, Alzheimer’s illness, Parkinson’s illness and quite a lot of different ailments neurodegenerative. For extra info, please go to the corporate’s web site at and comply with the corporate on Twitter @ProthenaCorp.

Ahead-Wanting Statements

This press launch comprises forward-looking statements. These claims handle, amongst different issues, the remedy potential, design, proposed mechanism of motion, and potential dosing of PRX012 and prasinezumab. These statements are based mostly on estimates, projections and assumptions which will show inaccurate and precise outcomes may differ materially from these anticipated resulting from recognized and unknown dangers, uncertainties and different components, together with however not restricted to these described within the “Dangers Elements” part. of our annual report on Kind 10-Ok filed with the Securities and Change Fee (SEC) on February 28, 2023 and discussions of potential dangers, uncertainties and different necessary components in our subsequent filings with the SEC. We undertake no obligation to publicly replace any forward-looking statements contained on this press launch on account of new info, future occasions, or modifications in our expectations.

* surrogate is outlined as an antibody recognizing the identical epitope as PRX012 and having the identical A-binding properties

+ lecanemab and donanemab utilized in these research have been generated by Prothena from publicly out there sequences

View the supply model at


Contact for media and traders:
Michael Bachner, senior director, company communications


Leave a Reply

Your email address will not be published. Required fields are marked *